T he Credit Valley Hospital (CVH) is a 300-bed institution situated in a rapidly growing, multicultural community. The hospital has active oncology (managing mainly solid tumour patients) and dialysis programs as well as geriatric rehabilitation, long term care and general surgery and paediatrics programs.
A major facet of antimicrobial stewardship at CVH has been the establishment of local clinical guidelines for the use of specific antimicrobial agents. Audits of physician compliance with guidelines are performed by drug utilization evaluation (DUE) pharmacists and the infectious diseases (ID) consultant. Guidelines for antimicrobial prescribing are published in a handbook that is revised biannually. Educational activities presented by pharmacists and the ID consultant attempt to reinforce physician compliance with clinical guidelines.
Antimicrobial agents are classified as open, reserved or nonformulary. Reserved and nonformulary agents are available without ID consultation or approval. An active pharmacist surveillance policy allows for immediate discussion of questionable prescriptions with prescribers, although no arbitration mechanism is available in the event of disagreement. Reserved antimicrobial agents are amikacin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, ciprofloxacin intravenous, fluconazole, vancomycin (intravenous and oral doses) and meropenem.
Intravenous vancomycin use has reduced by 60% at CVH over the past two years in response to Hospital Infection Control Practices Advisory Committee guidelines. Because of local susceptibilities to coagulase-negative Staphylococcus species, DUE pharmacists have argued against the use of intravenous vancomycin in the empirical management of continuous ambulatory peritoneal dialysis peritonitis. Initiatives to reduce vancomycin use further will include verification of penicillin allergy and possibly fucidic acid for orthopedic prophylaxis (already in use at the Orthopedic and Arthritic Hospital in Toronto, Ontario). Although oral vancomycin is still being used 'first line' for pseudomembranous colitis (PMC) by some physicians, a study may be undertaken comparing oral vancomycin with metronidazole in patients with a previous episode of PMC that did not respond to metronidazole. A study to prospectively examine the impact of reducing H 2 -blocker and proton-pump inhibitor therapy on the incidence of PMC and pneumonia in dialysis patients is also under consideration. A positive result for either or both of these studies might improve compliance with local guidelines for oral vancomycin use. Initial empirical management of febrile neutropenia is with cefazolin and gentamicin (multiple daily dosing). Only a small subset of febrile neutropenic patients in CVH appear to need broader subsequent coverage, although a more extensive review of the local experience with this regimen (incidence of breakthrough bacteremia in solid tumour patients versus patients with leukemia, need to expand coverage, duration of hospitalization and nephrotoxicity) is planned. The adoption of cefazolin/gentamicin treatment has led to the decreased use of cephalosporins in the oncology patient subgroup. This may be of benefit, as cephalosporin use in oncology patients has been implicated in the emergence of vancomycin-resistant enterococci in other centres (1, 2) .
Ciprofloxacin use has declined 30%, while step down and sequential therapy with oral ciprofloxacin are being readily adopted (50% of ciprofloxacin costs relate to oral ciprofloxacin). An aggressive pharmacy education and intervention program has played a major role in this success. This process included a chart review, followed by presentations of cases where use of ciprofloxacin was questionable. Pharmacists continue to routinely review patients on intravenous ciprofloxacin to determine whether alternatives (oral or other intravenous) are available.
Since its introduction to CVH in 1996, aminoglycoside once daily has not been readily adopted by physicians. Treating only a subgroup of patients (less than 70 years of age, with normal renal function, without confirmed abscess or pneumonia, not pregnant, not as the sole antipseudomonal agent in the treatment of febrile neutropenia) with aminoglycoside once daily might improve physicians' attitudes towards this dosing regimen. It is hoped that treatment with aminoglycoside once daily will lead to fewer clinical failures with aminoglycoside use (fewer cases with low peaks) and reduced third-generation cephalosporin use -the major reason for the promotion of this regimen at CVH.
Fluconazole has not regularly been used in accordance with local guidelines, although promotion of new Canadian guidelines for management of nosocomial Candida infections in non-neutropenic intensive care unit patients may lead to improvement in this area (3) .
No physician-pharmacist arbitration mechanism for the use of reserved antimicrobials is in place, although pharmacist intervention limits the use of these agents significantly. Depending on the results of future audits of restricted antimicrobial use, ID consultant approval might be sought for nonguideline use of reserved agents. There are no immediate plans to adopt an ID consultant approval system.
